Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,701.60
(
0.00%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
96.45
(
-4.67%
)
Bitcoin
76,567.46
(
-0.91%
)
News Focus
News Focus
Post# of 257628
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 213091

Monday, 09/11/2017 6:16:36 AM

Monday, September 11, 2017 6:16:36 AM

Post# of 257628
(ACHN/Medivir)—JNJ throws in the towel on HCV:

http://www.prnewswire.com/news-releases/janssen-to-discontinue-hepatitis-c-development-program-643657613.html

Janssen Sciences…today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir… This decision was made in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.

Inevitable and overdue.

Medivir (MVIR-B.ST) is down 8% today in Stockholm, implying that some investors didn’t realize JNJ’s HCV regimen was obsolete.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today